VIVUS (VVUS) Peers Tick Higher Amid Positive Qsymia Data (ARNA) (OREX)
Tweet Send to a FriendGet Alerts VVUS Hot Sheet
Trade VVUS Now!
VIVUS, Inc. (Nasdaq: VVUS) shares are ticking higher in early trading Friday morning following publication of positive results from a "study concluding that weight loss resulting from treatment with Qsymia (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions."
The article can be accessed here.
Also catching some positive sentiment today are VIVUS peers Arena Pharmaceuticals (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX). All three are positive ahead of the bell.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The article can be accessed here.
Also catching some positive sentiment today are VIVUS peers Arena Pharmaceuticals (Nasdaq: ARNA) and Orexigen (Nasdaq: OREX). All three are positive ahead of the bell.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Vivus (VVUS) Sees Upside on Icahn Connection
- InterOil (IOC) Enters negotiations with ExxonMobil (XOM) on Development Of The Elk And Antelope Resource
- 3D-Printer Saves Dying Baby (DDD) (SSYS) (XONE)
Create E-mail Alert Related Categories
FDA, Trader Talk
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
